MartinOkunMD

PubMed

• Patients' willingness to accept adverse event and cost tradeoffs from oral nicotinamide for reduced risk of non-melanoma skin cancer.
  Marco Boeri, Maral K Skelsey, James A Schiro, Susan E Dozier, Robert Glinert, Martin M Okun> ;The Journal of Dermatological Treatment. 2023 Dec 1
• Outcome Measures for the Evaluation of Treatment Response in Hidradenitis Suppurativa for Clinical Practice: A HiSTORIC Consensus Statement.
  Mastacouris, N., Tannenbaum, R., Strunk, A., Koptyev, J., Aarts, P., Alhusayen, R., Bechara, F., Benhadou, F., Bettoli, V., Brassard, A., Brown, D., Choon, S., Coutts,...> ;JAMA Dermatology. 2023 Nov 1
• 2 citations
  Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, do...
  Joslyn S Kirby, Martin M Okun, Afsaneh Alavi, Falk G Bechara, Christos C Zouboulis, Kurt Brown, Leandro L Santos, Annie Wang, Kristen B Bibeau, Alexa B Kimball, Porter...> ;Journal of the American Academy of Dermatology. 2024 Mar 1
• The promise of personalized medicine for hidradenitis suppurativa.
  Martin M Okun> ;The British Journal of Dermatology. 2023 Jan 23
• 2 citations
  Hidradenitis Suppurativa: Diagnosis and Management in the Emergency Department.
  Martin M Okun, Avram Flamm, Elizabeth Barrall Werley, Kirby, J.> ;The Journal of Emergency Medicine. 2022 Nov 1
• 2 citations
  Damage in hidradenitis suppurativa: a narrative review emphasizing the need for a novel outcome measure.
  Madelaine Fritsche, Martin Okun, Kirby, J.> ;The British Journal of Dermatology. 2022 Sep 1
• 66 citations
  What causes hidradenitis suppurativa ?-15 years after
  , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , > ;Experimental Dermatology. 2020 Dec 1
• 32 citations
  Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials.
  Gregor B.E. Jemec, Martin M. Okun, Seth B Forman, Wayne Gulliver, Errol P. Prens, Ulrich Mrowietz, April W. Armstrong, Ziqian Geng, Yihua Gu, David A. Williams, Henriq...> ;The British Journal of Dermatology. 2019 Nov 1
• 18 citations
  Adalimumab for nail psoriasis: efficacy and safety over 52 weeks from a phase-3, randomized, placebo-controlled trial.
  Boni E. Elewski, C.S. Baker, Jeffrey J. Crowley, Yves Poulin, Martin M. Okun, B. Calimlim, Ziqian Geng, O. Reyes Servin, Phoebe Rich> ;Journal of the European Academy of Dermatology and Venereology. 2019 Nov 1
• 102 citations
  Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study.
  Christos C. Zouboulis, Martin M. Okun, Errol P. Prens, Robert Gniadecki, Peter Foley, Charles Lynde, Jamie Weisman, Yihua Gu, David A. Williams, Gregor B.E. Jemec> ;Journal of the American Academy of Dermatology. 2019 Jan 1
• 15 citations
  Adalimumab Alleviates Skin Pain in Patients with Moderate to Severe Hidradenitis Suppurativa: Secondary Efficacy Results from the PIONEER I and PIONEER II Randomized C...
  Alexandra B. Kimball, Alan L. Shields, Stacie Hudgens, Martin M. Okun, Catherine Foley, Arijit Ganguli, Murali Sundaram> ;Journal of the American Academy of Dermatology. 2018 May 19
• 54 citations
  Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial
  Boni E. Elewski, Martin M. Okun, Kim A. Papp, Christopher M. Baker, Jeffrey J. Crowley, Gérard Guillet, Yves Poulin, Yihua Gu, Ziqian Geng, David A. Williams, Phoebe R...> ;Journal of the American Academy of Dermatology. 2018 Jan 1
• 31 citations
  Uncovering burden disparity: A comparative analysis of the impact of moderate-to-severe psoriasis and hidradenitis suppurativa
  Iltefat H. Hamzavi, Cynthia L Nicholson, Marko Zivkovic, Angela Parks-Miller, Jianyi Lee, Jingbo Yi, Yihua Gu, Martin M. Okun, Arijit Ganguli, Steve R. Arikian, Murali...> ;Journal of the American Academy of Dermatology. 2017 Dec 1
• 4 citations
  Poor early response to methotrexate portends inadequate long-term outcomes in patients with moderate-to-severe psoriasis: Evidence from 2 phase 3 clinical trials.
  Kenneth B. Gordon, Keith A. Betts, James Signorovitch, Junlong Li, Meng Xie, Eric Q. Wu, Martin M. Okun, Murali Sundaram> ;Journal of the American Academy of Dermatology. 2017 Dec 1
• Join now to see all